Amcomri Group PLC

By Financial Journalist: Alex Langton | 23 July 2026

There comes a point in small-cap investing when a company moves beyond simply asking investors to believe the story. Execution begins to replace expectation, and operational evidence starts to do the heavy lifting.

Amcomri Group reached that point with its FY25 results.

When we first featured Amcomri at 128p, the shares were soon comfortably ahead, reaching 163p in May; the timing proved encouraging. The investment case was never especially complicated: a disciplined industrial consolidator executing a proven buy-and-build strategy across resilient engineering markets, supported by prudent capital allocation and sensible financial discipline. April's FY25 results largely vindicated that thesis, providing tangible evidence that management was delivering against the strategy it had consistently articulated.

With the shares subsequently trading comfortably above our original feature price, the market appeared to be recognising that progress.

However, yesterday’s placing leaves me somewhat irked.

Not because insiders sold stock—indeed, there are perfectly rational arguments for broadening the shareholder register and improving liquidity—but because of how the transaction was structured. As discussed below, the process once again illustrates an all-too-familiar feature of AIM: when discounted shares are allocated, institutions are invited to participate, while existing retail shareholders are left to absorb the consequences from the sidelines.

In many respects, management did exactly what they said they would do. Yet the transaction highlights a long-standing feature of the AIM market that deserves greater scrutiny—not because Amcomri is unique, but because it is so typical.

The engineering group’s “Buy, Improve, Build” strategy has been well received by investors, and the company’s operational execution has generally inspired confidence. None of that changed when it announced the sale of 7.4m existing shares—equivalent to 10.29% of the issued share capital—at 135p, compared with the previous closing price of 152p.

This was not a fundraising. The company received no proceeds. Approximately £10m flowed entirely to five existing shareholders, four of whom were directors or their investment vehicles.

On the face of it, the rationale is entirely reasonable.

Prior to the transaction, Deputy Chairman and co-founder Paul McGowan beneficially owned almost 39% of the company, while major shareholder Jeffrey Hecktman controlled a further 13%. Such concentration inevitably restricts liquidity and can deter larger institutional investors who require a meaningful free float before committing capital.

Reducing that concentration is sensible corporate housekeeping rather than a sign of diminished conviction.

Indeed, the directors have gone out of their way to demonstrate precisely that. This represents the founders’ first meaningful realisation since establishing the business in 2022. McGowan still retains 32.58% of the company, while Chief Executive Hugh Whitcomb sold only around one quarter of his holding. All participating sellers have also agreed to a 12-month lock-up, reinforcing the message that this was intended to broaden the register rather than facilitate an exit.

Viewed purely through that lens, there is very little to criticise.

Where the Questions Begin

The issue is not why the shares were sold.

It is how they were sold.

The placing price of 135p was published in the launch announcement before the bookbuild opened.

That seemingly small detail fundamentally alters the nature of the transaction.

Accelerated bookbuilds are normally defended on practical grounds. Institutions bid overnight, demand determines price, and because pricing remains fluid there is little opportunity to accommodate retail participation.

That argument carries weight—when genuine price discovery is taking place.

Here, however, the price had already been determined.

The subsequent announcement confirmed the placing was oversubscribed.

Yet an oversubscribed placing at a pre-determined price is not evidence that the market discovered fair value. It is evidence that demand comfortably exceeded supply at the chosen price. This sort of gaslighting also irks.

That naturally raises a question.

Could the shares have been sold at a higher price?

Perhaps not materially so. But if institutional demand comfortably exceeded the stock available at 135p, it is reasonable to ask whether the 11.2% discount was larger than strictly necessary.

Ultimately, that cost was borne by every existing shareholder.

The Retail Question

It also raises another issue.

If the price was fixed before the process began, why were retail investors excluded?

The usual explanation—that an overnight institutional bookbuild cannot accommodate a simultaneous retail offer—appears considerably weaker when the placing price has already been established.

Platforms such as PrimaryBid and others have repeatedly demonstrated that fixed-price retail participation is perfectly achievable.

To be fair, there is a legitimate counterargument.

The objective was clearly to broaden institutional ownership and improve liquidity. Existing retail shareholders purchasing additional shares would do little to increase free float or attract larger funds.

That rationale is entirely understandable. But it also means retail investors absorbed the dilutionary effect of the discount while being denied the opportunity to participate on identical terms.

Institutions received the discounted shares. Retail investors simply watched the market price adjust.

One further point caught my attention.

The launch announcement disclosed outstanding Long-Term Incentive Plan awards, including approximately 800,000 options held by CEO Hugh Whitcomb and around 457,000 by Finance Director Neil O’Neill.

Those option disclosures do not appear in the results announcement. If they did, I missed it.

Whitcomb sold approximately 1.16m shares, reducing his reported holding to 4.83%.

However, once those outstanding options are considered, his overall exposure remains considerably higher than the headline shareholding alone might suggest.

I’m not suggesting there’s something improper about this.

The observation is simply that many investors read only the results announcement, not both RNS releases side by side — assuming they read past the headline. As a consequence, the market’s immediate impression of management alignment may be less complete than the underlying position warrants.

I’m just irked the process happened to favour one class of shareholder over another. That has become so commonplace on AIM that many investors scarcely notice it any longer.

Yet it remains a choice.

And where a placing price is fixed in advance at an 11% discount, it is reasonable to ask whether the shareholders funding that discount should at least have been given the opportunity to participate alongside the institutions benefiting from it.

Moan concluded.

Share

Opinions

We offer no advice and do not solicit the purchase of shares in any company we discuss. However, shares go up and down in value, making your financial situation risky.

The views and opinions contained within these editorials are for research purposes and are the opinions of the author(s). We aim to be as accurate as possible, but stress that you should also perform your research and never act solely on the contents of these editorials.